Compare Global Payments Inc (GPN) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global Payments Inc vs Recursion Pharmaceuticals Inc — how do they compare? Global Payments Inc trades at $88.64 (market cap $22.72B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: Global Payments Inc is far larger — about 12.6× Recursion Pharmaceuticals Inc's market cap, and Global Payments Inc pays a 1.16% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| GPN | RXRX | |
|---|---|---|
Market Cap | $22.72B | $1.81B |
Sector | Industrials | Health |
52-Week High | $90.01 | $6.79 |
52-Week Low | $62.47 | $2.84 |
Enterprise Value | $40.87B | $1.33B |
Dividend Yield | 1.16% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Global Payments (GPN) trades at $85.03, down 1.28% today, with a bullish technical signal from moving averages. Recent quarterly EPS beats and a consensus price target of $96.67 suggest upside potential, though negative net income margin and ROE highlight profitability challenges. Cash flow trends show strong operational performance, but rising debt-to-asset ratios warrant monitoring.
The outlook balances growth from Genius platform adoption against margin pressures and competitive fintech threats. Analysts are predominantly bullish, but investors should weigh earnings consistency against valuation risks and macroeconomic headwinds affecting payment volumes.
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global Payments Inc
Global Payments is a leading provider of payment processing and software solutions and focuses on serving small and midsize merchants. The company operates in 30 countries and generates about one fourth of its revenue from outside North America, primarily in Europe and Asia. In 2019, Global Payments merged with Total System Services in an all-stock deal that gave Total System Services shareholders 48% of the combined company's shares.
Read more on GPN →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
